| Popis: |
•AIM: This study aimed to evaluate the association between the pretreatment serum metrics and the best-corrected visual acuity (BCVA) of patients with macular edema (ME) secondary to retinal vein occlusion (RVO) and its subtypes after intravitreal ranibizumab or conbercept implantation.•METHODS: This retrospective observational study included 201 patients (201 eyes) who had been diagnosed with ME secondary to RVO at Heibei Eye Hospital between January 2020 and January 2021 and had received intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment. Serum metrics were measured before the first treatment, and the correlations between BCVA and each of the following four parameters—platelets, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR)—were analyzed to identify the predictors of effective intravitreal injection treatment outcomes.•RESULTS: The mean platelet level was significantly different between the effective and ineffective groups for RVO-ME (273.02±41.49 x109/L vs. 214.54±44.08 x109/L, P9/L vs. 214.72±40.42x109/L, P9/L vs. 209.27±42.91x109/L, PPP=0.003), and CRVO-ME (152.06±44.23 vs. 118.67±41.80, P=0.001). The cutoff value of the platelets was 126.734, the AUC was 0.699, and the sensitivity and specificity were 70.7% and 63.3%, respectively. There were no statistical differences between the effective and ineffective groups (RVO-ME and its subtypes) for NLR and MLR.•CONCLUSION: Higher pretreatment platelets and PLR were associated with BCVA in patients with RVO-ME and its subtypes who had been treated with anti-VEGF drugs. Platelets and PLR may be used as predictive and prognostic tools for effective intravitreal injection treatment outcomes. |
